Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates

Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults

Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482 · see citing works

Drug Transport across the Blood–Brain Barrier

Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994 · see citing works

The Effectiveness and Risks of Bariatric Surgery: An Updated Systematic Review and Meta-analysis, 2003-2012

Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688 · see citing works

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268 · see citing works

PROMALS3D: a tool for multiple protein sequence and structure alignments

Pei, J., Kim, B., & Grishin, N. V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn072 · Cited by 1,267 · see citing works

Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide

Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · see citing works

The Discovery and Development of Liraglutide and Semaglutide

Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · see citing works

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · see citing works

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · see citing works

Strategic Approaches to Optimizing Peptide ADME Properties

Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · see citing works

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · see citing works

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · see citing works

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · see citing works

Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist

Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · see citing works

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506 · see citing works

Bariatric surgery for obesity and metabolic disorders: state of the art

Nguyen, N. T., & Varela, J. E. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.170 · Cited by 505 · see citing works

The New Biology and Pharmacology of Glucagon

Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409 · see citing works

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · see citing works

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · see citing works

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

Campos, R. V., Lee, Y. C., & Drucker, D. J. (1994) · Endocrinology · doi:10.1210/endo.134.5.8156917 · Cited by 342 · see citing works

Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics

Erak, M., Bellmann‐Sickert, K., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.012 · Cited by 327 · see citing works

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · see citing works

GLP-1 Receptor Expression Within the Human Heart

Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works

Liraglutide for weight management: a critical review of the evidence

Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311 · see citing works

Absorption Enhancers: Applications and Advances

Aungst, B. J. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9307-4 · Cited by 309 · see citing works

Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

Glaesner, W., Vick, A., Millican, R. L., Ellis, B., Tschang, S., Tian, Y., Bokvist, K. B., Brenner, M. B., Köester, A., Pørksen, N. K., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305 · see citing works

Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials

Aguirre, T. A. S., Teijeiro‐Osorio, D., Rosa, M., Coulter, I. S., Alonso, M. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.004 · Cited by 300 · see citing works

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298 · see citing works

Bariatric surgery for type 2 diabetes

Dixon, J. B., le Roux, C. W., Rubino, F., & Zimmet, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60401-2 · Cited by 295 · see citing works

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30194-9 · Cited by 287 · see citing works

GLP-1 receptor agonists: a review of head-to-head clinical studies

Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · see citing works

Islet α cells and glucagon--critical regulators of energy homeostasis

Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266 · see citing works

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258 · see citing works

Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances

Ito, T., Igarashi, H., & Jensen, R. T. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.003 · Cited by 254 · see citing works

Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)

Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., & Brayden, D. J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020078 · Cited by 243 · see citing works

Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240 · see citing works

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · see citing works

Small-molecule agonists for the glucagon-like peptide 1 receptor

Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · see citing works

Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?

Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 230 · see citing works

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · see citing works

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

Koole, C., Wootten, D. L., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 225 · see citing works

The Impact of Diabetes and Diabetes Medications on Bone Health

Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 210 · see citing works

A Critical Analysis of the Clinical Use of Incretin-Based Therapies

Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205 · see citing works

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 203 · see citing works

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 201 · see citing works

Anti-obesity therapy: from rainbow pills to polyagonists

Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199 · see citing works

Passing the baton in class B GPCRs: peptide hormone activation via helix induction?

Parthier, C., Reedtz‐Runge, S., Rudolph, R., & Stubbs, M. T. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.004 · Cited by 193 · see citing works

The Crack-Up

Fitzgerald, F. S., & Wilson, E. (1945) · Cited by 183 · see citing works

Reappraisal of GIP Pharmacology for Metabolic Diseases

Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180 · see citing works

GLP-1/glucagon receptor co-agonism for treatment of obesity

Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · see citing works

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174 · see citing works

A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164 · see citing works

Orally Active Peptides: Is There a Magic Bullet?

Räder, A. F. B., Weinmüller, M., Reichart, F., Schumacher‐Klinger, A., Merzbach, S., Gilon, C., Hoffman, A., & Kessler, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807298 · Cited by 163 · see citing works

The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism

Wootten, D. L., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.023 · Cited by 161 · see citing works

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake

Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159 · see citing works

Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives

Bech, E. M., Pedersen, S. L., & Jensen, K. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00226 · Cited by 154 · see citing works

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · see citing works

Centrally Acting Agents for Obesity: Past, Present, and Future

Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151 · see citing works

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Smart, A. L., Gaisford, S., & Basit, A. W. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.917077 · Cited by 143 · see citing works

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · see citing works

Structure of the glucagon receptor in complex with a glucagon analogue

Zhang, H., Qiao, A., Yang, L., Eps, N. V., Frederiksen, K. S., Yang, D., Dai, A., Cai, X., Zhang, H., Yi, C., et al. (2018) · Nature · doi:10.1038/nature25153 · Cited by 141 · see citing works

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133 · see citing works

Extending the Structural View of Class B GPCRs

de Graaf, C., Song, G., Cao, C., Zhao, Q., Wang, M.-W., Wu, B., & Stevens, R. C. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.10.003 · Cited by 133 · see citing works

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132 · see citing works

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125 · see citing works

The Biology of Glucagon and the Consequences of Hyperglucagonemia

Albrechtsen, N. J. W., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 124 · see citing works

A novel glucagon-like peptide-1 (GLP-1)/Glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice

Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123 · see citing works

A novel <scp>GIP</scp> analogue, <scp>ZP</scp> 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116 · see citing works

Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase

Méry, P., Brechler, V., Pavoine, C., Pecker, F., & Fischmeister, R. (1990) · Nature · doi:10.1038/345158a0 · Cited by 113 · see citing works

Gut hormone polyagonists for the treatment of type 2 diabetes

Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 108 · see citing works

Monomeric GLP-1/GIP/Glucagon Triagonism Corrects Obesity, Hepatosteatosis, and Dyslipidemia in Female Mice

Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107 · see citing works

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · see citing works

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists

Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101 · see citing works

Peptide lipidation stabilizes structure to enhance biological function

Ward, B. P., Ottaway, N. L., Perez-Tilve, D., Ma, D., Gelfanov, V. M., Tschöp, M. H., & DiMarchi, R. D. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.08.008 · Cited by 101 · see citing works

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

Gasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 98 · see citing works

Glucagonoma syndrome: a review and update on treatment

John, A. M., & Schwartz, R. A. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13752 · Cited by 97 · see citing works

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95 · see citing works

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95 · see citing works

Newer GLP-1 receptor agonists and obesity-diabetes

Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 92 · see citing works

Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes

Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 87 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · see citing works

GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release

Sparre‐Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 81 · see citing works

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

Bhat, V. K., Kerr, B. D., Flatt, P. R., & Gault, V. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.009 · Cited by 75 · see citing works

MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study

Ambery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75 · see citing works

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist <scp>RG</scp> 7697 in people with type 2 diabetes mellitus

Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74 · see citing works

Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

Sharma, A. X., Quittner-Strom, E. B., Lee, Y., Johnson, J. A., Martin, S. A., Yu, X., Li, J., Lu, J., Cai, Z. P., Chen, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.065 · Cited by 72 · see citing works

Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69 · see citing works

Hemodynamic Effects of Glucagon: A Literature Review

Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2018-00050 · Cited by 68 · see citing works

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Bhat, V. K., Kerr, B. D., Vasu, S., Flatt, P. R., & Gault, V. A. (2013) · Diabetologia · doi:10.1007/s00125-013-2892-2 · Cited by 66 · see citing works

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE−/− mice by blocking monocyte/macrophage activation

Kahles, F., Liberman, A., Halim, C., Rau, M., Möllmann, J., Mertens, R. W., Rückbeil, M. V., Diepolder, I., Walla, B., Diebold, S., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.014 · Cited by 64 · see citing works

Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles

Bueno, A. B., Showalter, A. D., Wainscott, D. B., Stutsman, C., Marín, A., FICORILLI, J. V., Cabrera, O., Willard, F. S., & Sloop, K. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696039 · Cited by 60 · see citing works

Peptibodies: An elegant solution for a long‐standing problem

Cavaco, M. C., Castanho, M. A. R. B., & Neves, V. (2017) · Peptide Science · doi:10.1002/bip.23095 · Cited by 58 · see citing works

The new era of drug therapy for obesity: the evidence and the expectations

Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58 · see citing works

Localization of the Domains Involved in Ligand Binding and Activation of the Glucose-Dependent Insulinotropic Polypeptide Receptor

Gelling, R. W., Wheeler, M. B., Xue, J., Gyomorey, S., Nian, C., Pederson, R. A., & McIntosh, C. H. S. (1997) · Endocrinology · doi:10.1210/endo.138.6.9104 · Cited by 51 · see citing works

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations

Evers, A., Bossart, M., Pfeiffer‐Marek, S., Elvert, R., Schreuder, H., Kurz, M. E., Stengelin, S., Lorenz, M., Herling, A. W., Konkar, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00292 · Cited by 50 · see citing works

Discovery of ( S )-2-Cyclopentyl- N -((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1 H -pyrrido[3,4- b ]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM)

Morris, L. C., Nance, K. D., Gentry, P. R., Days, E., Weaver, C. D., Niswender, C. M., Thompson, A. D., Jones, C. K., Locuson, C. W., Morrison, R. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501375c · Cited by 49 · see citing works

Does glucagon have a positive inotropic effect in the human heart?

Hernández-Cascales, J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0791-z · Cited by 47 · see citing works

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

Irwin, N., Hunter, K., Frizzell, N., & Flatt, P. R. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.11.007 · Cited by 38 · see citing works

Potent Prearranged Positive Allosteric Modulators of the Glucagon‐like Peptide‐1 Receptor

Jones, B. J., Scopelliti, R., Tomás, A., Bloom, S. R., Hodson, D. J., & Broichhagen, J. (2017) · ChemistryOpen · doi:10.1002/open.201700062 · Cited by 38 · see citing works

Gastric inhibitory polypeptide receptor antagonist, SKL‐14959, suppressed body weight gain on diet‐induced obesity mice

Nakamura, T., Tanimoto, H., Mizuno, Y., Okamoto, M., Takeuchi, M., Tsubamoto, Y., & Noda, H. (2018) · Obesity Science & Practice · doi:10.1002/osp4.164 · Cited by 38 · see citing works

Transmucosal Absorption Enhancers in the Drug Delivery Field

Maher, S., Casettari, L., & Illum, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070339 · Cited by 37 · see citing works

The unrelenting fall of the pharmacological treatment of obesity

Dalmazi, G. D., Vicennati, V., Pasquali, R., & Pagotto, U. (2013) · Endocrine · doi:10.1007/s12020-013-9983-1 · Cited by 29 · see citing works

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure

Gao, C., Ren, S. V., Yu, J., Baal, U. H., Thai, D. L., Lu, J., Zeng, C., Yan, H., & Wang, Y. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.001 · Cited by 28 · see citing works

Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues

Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24 · see citing works

Multifunctional Antibody Agonists Targeting Glucagon‐like Peptide‐1, Glucagon, and Glucose‐Dependent Insulinotropic Polypeptide Receptors

Wang, Y., Du, J., Zou, H., Liu, Y., Zhang, Y., González, J., Chao, E., Lu, L., Yang, P., Parker, H., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201606321 · Cited by 23 · see citing works

Optimization of peptide-based polyagonists for treatment of diabetes and obesity

Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 23 · see citing works

An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon‐Like Peptide‐1 Receptor

Šmelcerović, A., Lazarević, J., Tomović, K., Anastasijevic, M., Jukič, M., Kocic, G. M., & Anderluh, M. (2019) · ChemMedChem · doi:10.1002/cmdc.201800699 · Cited by 19 · see citing works

Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities

Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17 · see citing works

Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models

KIM, J. A., LEE, S., LEE, S. H., JUNG, S. Y., KIM, Y. H., CHOI, I. Y., & KIM, S. J. (2018) · Diabetes · doi:10.2337/db18-1107-p · Cited by 14 · see citing works

OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys

KAWAI, T., TANINO, F., Fukazawa, M., OGAWA, K., Nagao, S., Yoshino, H., KOMATSU, S.-I., SUZUKI, Y., & Kawabe, Y. (2018) · Diabetes · doi:10.2337/db18-1118-p · Cited by 13 · see citing works

Review: Bariatric surgery: to treat diabesity

Flatt, P. R., Day, C., & Bailey, C. J. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409103927 · Cited by 10 · see citing works

Multi-functional Chimeric Peptides: The More the Merrier

Singh, A., & Srivastava, V. P. (2018) · Protein and Peptide Letters · doi:10.2174/0929866525666181120090857 · Cited by 8 · see citing works

990-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model

KIM, J. K., Lee, J. S., Kim, D., Park, E., Kim, Y. H., & CHOI, I. Y. (2019) · Diabetes · doi:10.2337/db19-990-p · Cited by 7 · see citing works

G protein-coupled receptors: structure- and function-based drug discovery

Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 641 · see citing works

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology &amp; Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · see citing works

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 147 · see citing works

Tirzepatide: A Systematic Update

Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118 · see citing works

The molecular pharmacology of glucagon agonists in diabetes and obesity

Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82 · see citing works

The incretin/glucagon system as a target for pharmacotherapy of obesity

Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77 · see citing works

Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes

Frías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 73 · see citing works

Proglucagon-Derived Peptides as Therapeutics

Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 70 · see citing works

Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives

Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 61 · see citing works

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems

Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55 · see citing works

Recent progress in assays for GPCR drug discovery

Guo, S., Zhao, T., Yun, Y., & Xie, X. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00464.2021 · Cited by 53 · see citing works

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency

Puszkarska, A. M., Taddese, B., Revell, J. D., Davies, G., Field, J., Hornigold, D. C., Buchanan, A. G., Vaughan, T. J., & Colwell, L. J. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01532-x · Cited by 43 · see citing works

Structural analysis of the dual agonism at GLP-1R and GCGR

Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 42 · see citing works

GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism

Boer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38 · see citing works

Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide

Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Li, Z., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 39 · see citing works

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 34 · see citing works

The role of cereal soluble fiber in the beneficial modulation of glycometabolic gastrointestinal hormones

Kabisch, S., Weickert, M. O., & Pfeiffer, A. F. H. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2141190 · Cited by 31 · see citing works

Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes

Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 32 · see citing works

Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region

Bowker, N., Hansford, R., Burgess, S., Foley, C. N., Auyeung, V. P. W., Erzurumluoglu, A. M., Stewart, I. D., Wheeler, E., Pietzner, M., Gribble, F. M., et al. (2021) · Diabetes · doi:10.2337/db21-0103 · Cited by 24 · see citing works

The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines

Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 23 · see citing works

Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application

Kim, J., Kim, J., Choi, C., Bae, J., & Choi, H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01497-y · Cited by 25 · see citing works

GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo

Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B. J., Tomás, A., Mayor, F., & Murga, C. (2021) · BMC Biology · doi:10.1186/s12915-021-00966-w · Cited by 18 · see citing works

The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases

Chen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11 · see citing works

A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity

Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 11 · see citing works

Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management

Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 11 · see citing works

Current Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia

Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 11 · see citing works

Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides

Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 12 · see citing works

Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor

Yuliantie, E., van der Velden, W. J. C., Labroska, V., Dai, A., Zhao, F., Darbalaei, S., Deganutti, G., Xu, T., Zhou, Q., Yang, D., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114715 · Cited by 10 · see citing works

Free fatty acids, glicentin and glucose-dependent insulinotropic polypeptide as potential major determinants of fasting substrate oxidation

Hummel, J., Fritsche, L., Vosseler, A., Dannecker, C., Hoene, M., Kantartzis, K., Häring, H., Stefan, N., Machann, J., Birkenfeld, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95750-9 · Cited by 7 · see citing works

Amplifying the antidiabetic actions of glucagon‐like peptide‐1: Potential benefits of new adjunct therapies

Tanday, N., Flatt, P. R., & Irwin, N. (2021) · Diabetic Medicine · doi:10.1111/dme.14699 · Cited by 10 · see citing works

Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists

Darbalaei, S., Chang, R., Zhou, Q., Chen, Y., Dai, A., Wang, M., & Yang, D. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00962-y · Cited by 9 · see citing works

Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review

Conlon, J. M., O'Harte, F. P. M., & Flatt, P. R. (2021) · Peptides · doi:10.1016/j.peptides.2021.170706 · Cited by 9 · see citing works

Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice

Leuthardt, A. S., Boyle, C. N., Raun, K., Lutz, T. A., John, L. M., & Foll, C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175912 · Cited by 9 · see citing works

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

Rees, T. A., Buttle, B., Tasma, Z., Yang, S.-H., Harris, P. W. R., & Walker, C. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1463313 · Cited by 7 · see citing works

Implication of sugar, protein and incretins in excessive glucagon secretion in type 2 diabetes after mixed meals

Zhang, J., Schaefer, S. M., Kabisch, S., Csanalosi, M., Schuppelius, B., Kemper, M., Markova, M., Meyer, N. M. T., Pivovarova‐Ramich, O., Keyhani‐Nejad, F., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.011 · Cited by 6 · see citing works

Innovative Glucagon-based Therapies for Obesity

Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 5 · see citing works

News ways of understanding the complex biology of diabetes using PET

Eriksson, O., Långström, B., & Antoni, G. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.04.004 · Cited by 5 · see citing works

Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease

Wong, A., Guduri, S., Chen, T.-Y., & Patel, K. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1687617 · Cited by 4 · see citing works

Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice

Franklin, Z. J., Lafferty, R. A., Flatt, P. R., McShane, L. M., O'Harte, F. P. M., & Irwin, N. (2022) · Biochimie · doi:10.1016/j.biochi.2022.04.005 · Cited by 3 · see citing works

Recent advances in peptide-based therapy for Type 2 diabetes and obesity

Conlon, J. M., Flatt, P. R., & Bailey, C. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170652 · Cited by 3 · see citing works

Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases

Zhou, C., Gong, B., Liu, X., Hu, G., & Sun, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177681 · Cited by 2 · see citing works

Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease

Allen, M. R., Metzger, C. E., Chen, N. X., Tinsley, I. C., DiMarchi, R. D., O’Neill, K. D., Matter, E. K., & Moe, S. M. (2026) · Bone · doi:10.1016/j.bone.2026.117933 · Cited by 1 · see citing works

The causes of obesity relapse after weight loss

Guseinova, R. M., Владимировна, Д. А., Vasyukova, O. V., Shestakova, E. A., Okorokov, P. L., & Mokrysheva, N. G. (2023) · Problems of Endocrinology · doi:10.14341/probl13275 · Cited by 1 · see citing works

The ever increasing peptide journey

Herzig, K. (2021) · Peptides · doi:10.1016/j.peptides.2021.170684

屈折管内の流れに関する研究 : 第7報-乱流における流動機構の数値的研究

嵩, 哲., & 藤井, 清. (1983) · 空気調和・衛生工学会論文集

Editorial: Special issue novel aspects of islet peptides

Eliasson, L., & Wierup, N. (2022) · Peptides · doi:10.1016/j.peptides.2022.170879

Additional file 1 of GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo

Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B., Tomás, A., Mayor, F., & Murga, C. (2021) · Figshare · doi:10.6084/m9.figshare.14157718

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Kostadinova, K. A., Venne, J. L., Krajčovičová, S., Dodgson, J., Hogendorf, W. F. J., Nielsen, T. E., Hymel, D., Bolt, H. L., Collinson, A., Day, J., et al. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71280

Recent Advances in the Synthesis of Therapeutic Peptides and Oligonucleotides

Ramesh, A., Behera, P., Siddija, R., Ghosh, S., & Tiwari, O. S. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00322

BindingDB Entry 50017128: The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases.

BindingDB (2023) · UC San Diego · doi:10.7270/q2n87fvh

Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors

Khajavi, N., Biebermann, H., Tschöp, M. H., & DiMarchi, R. D. (2017) · Endocrine development · doi:10.1159/000475737 · Cited by 18 · see citing works

GLP-1/glucagon receptor co-agonism for treatment of obesity

Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · see citing works

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists

Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81 · see citing works

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · see citing works

Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives

Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14 · see citing works